2025
Rapid response to behavioral/pharmacological obesity treatments for binge‐eating disorder predicts better clinical outcomes
Lydecker J, Gueorguieva R, Grilo C. Rapid response to behavioral/pharmacological obesity treatments for binge‐eating disorder predicts better clinical outcomes. Obesity 2025, 33: 1067-1075. PMID: 40265670, DOI: 10.1002/oby.24292.Peer-Reviewed Original ResearchConceptsBinge-eating disorderBinge-eating remissionEating-disorder psychopathologyAssociated with greater reductionsObesity treatmentCo-occurring obesityBinge-eating frequencyClinical trial testingBehavioral therapyNon-rapid responseGreater reductionsPercent weight lossNaltrexone/bupropionRandomized clinical trial testingDisordersPrognostic significanceParticipantsPosttreatmentClinical characteristicsPrognostic indicatorClinical outcomesMetabolic outcomesResponse effectMetabolic variablesObesity interventionsA randomized, placebo-controlled, double-blind, pilot study of cannabis-related driving impairment assessed by driving simulator and self-report
Meda S, Stevens M, Boer E, Pittman B, Gueorguieva R, Huestis M, Pearlson G. A randomized, placebo-controlled, double-blind, pilot study of cannabis-related driving impairment assessed by driving simulator and self-report. Journal Of Psychopharmacology 2025, 39: 364-372. PMID: 40077985, DOI: 10.1177/02698811251324379.Peer-Reviewed Original ResearchConceptsCannabis-induced impairmentBlood THC levelsDouble-blindCannabis useVaporized cannabisTHC levelsActual impairmentAcute doseWithin-subjectSelf-reportSimulated driving testDrug effectsDriving impairmentPlacebo-controlledImpairment indicatorsImpairmentCannabisAssessment daysEffect of doseParticipants' willingnessPost-doseTHCBehavioral metricsCar-followingParticipantsSwitching from menthol to non-menthol cigarettes does not impact acute responses to intravenous nicotine
Wolkowicz N, Parida S, Gueorguieva R, Sofuoglu M. Switching from menthol to non-menthol cigarettes does not impact acute responses to intravenous nicotine. Pharmacology Biochemistry And Behavior 2025, 249: 173985. PMID: 40010441, PMCID: PMC11932434, DOI: 10.1016/j.pbb.2025.173985.Peer-Reviewed Original ResearchConceptsContinuous Performance TestResponse to nicotineNicotine infusionNon-menthol cigarettesAcute responses to nicotineExperimental sessionsIntravenous nicotine infusionsNicotine metabolite ratioSmoking conditionsDaily cigarette smokingTobacco withdrawalWithdrawal severitySmoking urgesNicotine administrationCigarette consumptionIntravenous nicotineSmoking menthol cigarettesDrug effectsNicotineReduce cigarette consumptionHeart rate responseMetabolite ratiosBlood levelsPrimary outcomeInfusion periodThe effect of inpatient brief cognitive-behavioral therapy for suicide prevention on post-discharge emergency department utilization: Secondary analysis of a randomized clinical trial
Diefenbach G, Collett S, Black S, Rudd M, Gueorguieva R, Tolin D. The effect of inpatient brief cognitive-behavioral therapy for suicide prevention on post-discharge emergency department utilization: Secondary analysis of a randomized clinical trial. General Hospital Psychiatry 2025, 93: 73-79. PMID: 39837259, DOI: 10.1016/j.genhosppsych.2025.01.007.Peer-Reviewed Original ResearchConceptsSubstance use disordersBrief cognitive-behavioral therapyCognitive-behavioral therapyED visitsSuicide preventionSecondary analysisEmergency departmentSuicide-related ED visitsHistory of suicide attemptsEmergency department utilizationElectronic medical record reviewPost-discharge emergency departmentMedical record reviewED utilizationPsychiatric readmissionTreatment effectsSuicide attemptsUse disorderRecord reviewSelf-reportRandomized clinical trialsGeneralized linear modelVisitsSuicidePost-discharge ED visits
2024
Smartband-based smoking detection and real-time brief mindfulness intervention: findings from a feasibility clinical trial
Horvath M, Pittman B, O’Malley S, Grutman A, Khan N, Gueorguieva R, Brewer J, Garrison K. Smartband-based smoking detection and real-time brief mindfulness intervention: findings from a feasibility clinical trial. Annals Of Medicine 2024, 56: 2352803. PMID: 38823419, PMCID: PMC11146247, DOI: 10.1080/07853890.2024.2352803.Peer-Reviewed Original ResearchConceptsBrief mindfulness interventionsMindfulness exercisesTreatment startersMindfulness interventionSmoking interventionsOnline mindfulness trainingWhite non-HispanicMindfulness trainingTreatment fidelityFeasibility measuresHelpfulness ratingsNon-HispanicDaily smokersPredicting smokingReduce smokingExerciseSmokingCigarette smokingInterventionLow completenessAdherenceParticipantsSmartbandAcceptanceMindfulnessA randomized controlled trial of potential tobacco policies prohibiting menthol flavor in cigarettes and e-cigarettes: a study protocol
Bold K, Sharma A, Haeny A, Gueorguieva R, Buta E, Baldassarri S, Lempert L, Krishnan-Sarin S, O’Malley S. A randomized controlled trial of potential tobacco policies prohibiting menthol flavor in cigarettes and e-cigarettes: a study protocol. BMC Psychiatry 2024, 24: 201. PMID: 38475757, PMCID: PMC10935798, DOI: 10.1186/s12888-024-05619-0.Peer-Reviewed Original ResearchConceptsSmoking menthol cigarettesE-cigarettesCigarette useReduce tobacco-related health disparitiesTobacco-related health disparitiesMenthol cigarettesRates of menthol cigarette useTobacco use statusMenthol cigarette useRandomized controlled trialsPublic health problemHealth disparitiesTobacco policiesFlavored e-cigarettesSmoke-freeMenthol flavorsMenthol policiesBlack adultsQuit smokingNon-Black participantsSmoking behaviorFollow-up visitHealth problemsSecondary outcomesE-cigarette products
2023
Naltrexone plus bupropion combination medication maintenance treatment for binge-eating disorder following successful acute treatments: randomized double-blind placebo-controlled trial
Grilo C, Lydecker J, Gueorguieva R. Naltrexone plus bupropion combination medication maintenance treatment for binge-eating disorder following successful acute treatments: randomized double-blind placebo-controlled trial. Psychological Medicine 2023, 53: 7775-7784. PMID: 37366017, PMCID: PMC10751383, DOI: 10.1017/s0033291723001800.Peer-Reviewed Original ResearchConceptsNaltrexone/bupropionBinge-eating disorderBinge-eating remissionAcute treatmentMaintenance treatmentBinge-eating frequencyDouble-blind placebo-controlled trialBehavioral weight loss therapyWeight lossCo-occurring obesitySuccessful acute treatmentPlacebo-controlled trialWeight loss therapySignificant additional weight lossSingle-site trialAdditional weight lossAcute efficacyRemission rateAdult patientsComorbid obesityBupropionInitial interventionPosttreatment assessmentRespondersPlaceboCognitive‐behavioral therapy for binge‐eating disorder for non‐responders to initial acute treatments: Randomized controlled trial
Grilo C, Lydecker J, Gueorguieva R. Cognitive‐behavioral therapy for binge‐eating disorder for non‐responders to initial acute treatments: Randomized controlled trial. International Journal Of Eating Disorders 2023, 56: 1544-1553. PMID: 37144325, PMCID: PMC10524840, DOI: 10.1002/eat.23975.Peer-Reviewed Original ResearchConceptsInitial acute treatmentBinge-eating disorderCognitive behavioral therapyAcute treatmentBinge-eating frequencyInitial interventionTherapist-led cognitive behavioural therapyInitial pharmacological treatmentTreat remission ratesEvidence-based treatmentsSingle-site trialAcute efficacyRemission rateAdult patientsInitial treatmentPharmacological treatmentPatientsPosttreatment assessmentBehavioral treatmentSufficient benefitTherapyDisordersInterventionTreatmentPharmacotherapy
2022
Predictors of abstinence, no heavy drinking days, and a 2‐level reduction in World Health Organization drinking levels during treatment for alcohol use disorder in the COMBINE study
Wallach JD, Gueorguieva R, Phan H, Witkiewitz K, Wu R, O'Malley SS. Predictors of abstinence, no heavy drinking days, and a 2‐level reduction in World Health Organization drinking levels during treatment for alcohol use disorder in the COMBINE study. Alcohol Clinical And Experimental Research 2022, 46: 1331-1339. PMID: 35616436, PMCID: PMC9887652, DOI: 10.1111/acer.14877.Peer-Reviewed Original ResearchConceptsHeavy drinking daysWeeks of treatmentAlcohol use disorderDependence Scale scoresDrinking daysScale scoreDays abstinentPredictors of abstinenceConsecutive weeksUse disordersDrinking levelsCOMBINE StudyOlder subjectsRandomized placebo-controlled trialPlacebo-controlled trialEfficacy of naltrexoneMultiple patient characteristicsTrials of medicationsBehavioral intervention studyPatient characteristicsFuture trialsBaseline variablesCombined PharmacotherapiesYoung subjectsComplete abstinenceClinical and Financial Outcomes Associated With a Workplace Mental Health Program Before and During the COVID-19 Pandemic
Bondar J, Morrow C, Gueorguieva R, Brown M, Hawrilenko M, Krystal JH, Corlett PR, Chekroud AM. Clinical and Financial Outcomes Associated With a Workplace Mental Health Program Before and During the COVID-19 Pandemic. JAMA Network Open 2022, 5: e2216349. PMID: 35679044, PMCID: PMC9185188, DOI: 10.1001/jamanetworkopen.2022.16349.Peer-Reviewed Original ResearchConceptsMental health programsHealth programsCohort studyLarge clinical effect sizesPatient Health Questionnaire-9Common mental health conditionsSheehan Disability ScaleClinical effect sizeMental health conditionsMental health symptomsCost of treatmentGeneralized anxiety disorderMental health difficultiesMental health benefitsWorkplace wellness programsCare navigationClinical improvementPrimary outcomeClinical benefitQuestionnaire-9Disability ScaleMedication managementLeast moderate anxietyMixed-effects regressionPerson psychotherapySensitivity, specificity, and tolerability of the BACTrack Skyn compared to other alcohol monitoring approaches among young adults in a field‐based setting
Ash GI, Gueorguieva R, Barnett NP, Wang W, Robledo DS, DeMartini KS, Pittman B, Redeker NS, O’Malley S, Fucito LM. Sensitivity, specificity, and tolerability of the BACTrack Skyn compared to other alcohol monitoring approaches among young adults in a field‐based setting. Alcohol Clinical And Experimental Research 2022, 46: 783-796. PMID: 35567595, PMCID: PMC9179100, DOI: 10.1111/acer.14804.Peer-Reviewed Original ResearchDevelopment of pulsed intravenous nicotine infusions as a model for inhaled nicotine in humans
De Aquino JP, DeVito EE, Xie C, Meyerovich J, Parida S, Gueorguieva R, Sofuoglu M. Development of pulsed intravenous nicotine infusions as a model for inhaled nicotine in humans. Psychopharmacology 2022, 239: 2809-2818. PMID: 35554617, DOI: 10.1007/s00213-022-06162-0.Peer-Reviewed Original ResearchLongitudinal Trajectories of Multiple Nicotine Product Use Among Youths in the Population Assessment of Tobacco and Health Study
Simon P, Jiang Y, Buta E, Sartor CE, Krishnan-Sarin S, Gueorguieva R. Longitudinal Trajectories of Multiple Nicotine Product Use Among Youths in the Population Assessment of Tobacco and Health Study. JAMA Network Open 2022, 5: e223549. PMID: 35319763, PMCID: PMC8943628, DOI: 10.1001/jamanetworkopen.2022.3549.Peer-Reviewed Original ResearchConceptsNicotine product useCigar useTobacco usersTobacco useHealth StudyCigarette useProduct useWave 1Significant public health concernLongitudinal trajectoriesPublic health concernNon-Hispanic whitesTobacco product useLogistic regression modelsTobacco use behaviorsComplex survey designMultinomial logistic regression modelsDays of useSocioecological factorsMAIN OUTCOMESmokeless tobaccoLower oddsNicotine productsLatent class growth analysisSociodemographic factorsImpact of delivery rate on the acute response to intravenous nicotine: A human laboratory study with implications for regulatory science
De Aquino JP, MacLean RR, Gueorguieva R, DeVito EE, Eid T, Sofuoglu M. Impact of delivery rate on the acute response to intravenous nicotine: A human laboratory study with implications for regulatory science. Addiction Biology 2022, 27: e13161. PMID: 35229960, PMCID: PMC8903077, DOI: 10.1111/adb.13161.Peer-Reviewed Original ResearchConceptsAbuse potentialPositive subjective drug effectsSubjective drug effectsHuman laboratory studiesPositive subjective effectsAttention functionSmoking urgesOvernight abstinencePotential therapeutic effectsEffects of nicotineHeart rate increaseDelivery rateDependent smokersExperimental sessionsSubjective effectsNicotine dependenceIntravenous nicotineBlood pressureSaline infusionAcute effectsTherapeutic effectHeart rateDrug effectsAcute responseCrossover design
2021
Dynamic structural equation modeling of the relationship between alcohol habit and drinking variability
DeMartini KS, Gueorguieva R, Taylor JR, Krishnan-Sarin S, Pearlson G, Krystal JH, O'Malley SS. Dynamic structural equation modeling of the relationship between alcohol habit and drinking variability. Drug And Alcohol Dependence 2021, 233: 109202. PMID: 35151022, PMCID: PMC10046111, DOI: 10.1016/j.drugalcdep.2021.109202.Peer-Reviewed Original ResearchDopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia
Abi-Dargham A, Javitch JA, Slifstein M, Anticevic A, Calkins ME, Cho YT, Fonteneau C, Gil R, Girgis R, Gur RE, Gur RC, Grinband J, Kantrowitz J, Kohler C, Krystal J, Murray J, Ranganathan M, Santamauro N, Van Snellenberg J, Tamayo Z, Wolf D, D’Souza D, Srihari V, Gueorguieva R, Patel P, Forselius-Bielen K, Lu J, Butler A, Fram G, Afriyie-Agyemang Y, Selloni A, Cadavid L, Gomez-Luna S, Gupta A, Radhakrishnan R, Rashid A, Aker R, Abrahim P, Nia A, Surti T, Kegeles L, Carlson M, Goldberg T, Gangwisch J, Benedict E, Govil P, Brazis S, Mayer M, de la Garrigue N, Fallon N, Baumvoll T, Abeykoon S, Perlman G, Bobchin K, Elliott M, Schmidt L, Rush S, Port A, Heffernan Z, Laney N, Kantor J, Hohing T, Gray D, Lieberman J. Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia. Schizophrenia Bulletin 2021, 48: 199-210. PMID: 34423843, PMCID: PMC8781338, DOI: 10.1093/schbul/sbab095.Peer-Reviewed Original ResearchConceptsCortical dopamine neurotransmissionPositive allosteric modulationImportant therapeutic targetPF-06412562Dopaminergic receptorsD1R stimulationDA levelsTolerable dosesLevel of stimulationDopamine neurotransmissionReceptor stimulationTherapeutic targetPartial agonistCognitive deficitsBiased agonismFull agonismTarget engagementAllosteric modulationNew drugsStimulationPoor bioavailabilitySchizophreniaOptimal stimulationDrugsExpression levelsIndividual Differences in the Associations Between Risk Factors for Alcohol Use Disorder and Alcohol Use-Related Outcomes
Haeny AM, Gueorguieva R, Jackson A, Morean ME, Krishnan-Sarin S, DeMartini KS, Pearlson GD, Anticevic A, Krystal JH, O’Malley S. Individual Differences in the Associations Between Risk Factors for Alcohol Use Disorder and Alcohol Use-Related Outcomes. Psychology Of Addictive Behaviors 2021, 35: 501-513. PMID: 34110841, PMCID: PMC9211405, DOI: 10.1037/adb0000733.Peer-Reviewed Original ResearchExamining depression scores as predictors and moderators of treatment outcomes in patients with binge‐eating disorder
Grilo CM, Gueorguieva R, Pittman B. Examining depression scores as predictors and moderators of treatment outcomes in patients with binge‐eating disorder. International Journal Of Eating Disorders 2021, 54: 1555-1559. PMID: 34137474, DOI: 10.1002/eat.23569.Peer-Reviewed Original ResearchConceptsCognitive behavioral therapyBinge-eating disorderEvidence-based psychological interventionsDepression scoresEating Disorder PsychopathologyBinge-eating frequencyPredictors/moderatorsModerators of responseElevated depression scoresPsychological interventionsBWL interventionModeratorTreatment outcomesBaseline depression scoresLong-term outcomesBWLModerate outcomeFindings reinforceDepressionScoresDisordersInterventionPsychopathologyEarly changesPatientsThe effect of varenicline on smoking and drinking outcomes among Black and White adults with alcohol use disorder and co-occurring cigarette smoking: A secondary analysis of two clinical trials
Haeny AM, Gueorguieva R, Montgomery L, Bold KW, Fucito LM, Wu R, Muvvala SB, Zweben A, O'Malley SS. The effect of varenicline on smoking and drinking outcomes among Black and White adults with alcohol use disorder and co-occurring cigarette smoking: A secondary analysis of two clinical trials. Addictive Behaviors 2021, 122: 106970. PMID: 34216871, PMCID: PMC9426655, DOI: 10.1016/j.addbeh.2021.106970.Peer-Reviewed Original ResearchConceptsEffects of vareniclineAlcohol use disorderCigarette smokingClinical trialsUse disordersWhite adultsEfficacy of vareniclineNumber of drinksVareniclineSmokingPrimary analysisAlcohol treatmentSecondary analysisAlcohol useTrialsBlack participantsDrinking outcomesLinear mixed modelsAdultsWhite peopleWhite participantsMixed modelingCigarettesDisordersTreatmentMapping data‐driven individualized neurobehavioral phenotypes in heavy alcohol drinkers
DeMartini KS, Gueorguieva R, Pearlson G, Krishnan‐Sarin S, Anticevic A, Ji LJ, Krystal JH, O’Malley S. Mapping data‐driven individualized neurobehavioral phenotypes in heavy alcohol drinkers. Alcohol Clinical And Experimental Research 2021, 45: 841-853. PMID: 33605439, DOI: 10.1111/acer.14580.Peer-Reviewed Original ResearchConceptsConfirmatory factor analysisIncentive salienceNeurofunctional domainsAlcohol use disorderExecutive functionLatent factorsPhysical neglectSelf-report measuresChildhood emotional abuseUse disordersChildhood physical neglectEarly life stressSignificant predictorsMultiple significant predictorsMultiple causes modelCurrent AUDNegative emotionalityAddiction developmentEmotional abuseChildhood neglectFactor structureDrinking frequencySalienceCause modelFactor analysis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply